128 related articles for article (PubMed ID: 29225856)
21. A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman.
ElSalem S; Elawad S; Ahmed A; AlSaadi M; AlHail M
Eur J Hosp Pharm; 2019 May; 26(3):170-172. PubMed ID: 31428326
[TBL] [Abstract][Full Text] [Related]
22. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007.
Garratty G; Arndt PA
Immunohematology; 2014; 30(2):66-79. PubMed ID: 25247621
[TBL] [Abstract][Full Text] [Related]
23. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis.
Reichardt P; Handrick W; Linke A; Schille R; Kiess W
Infection; 1999; 27(6):355-6. PubMed ID: 10624596
[TBL] [Abstract][Full Text] [Related]
24. Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the 'immune complex' method.
Arndt PA; Garratty G; Hill J; Kasper M; Chandrasekaran V
Vox Sang; 2002 Oct; 83(3):273-8. PubMed ID: 12366773
[TBL] [Abstract][Full Text] [Related]
25. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
26. Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
Nguyen VD; Tourigny JF; Roy R; Brouillette D
Pharmacotherapy; 2015 Dec; 35(12):e326-30. PubMed ID: 26684560
[TBL] [Abstract][Full Text] [Related]
27. Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
Beaulieu C; Kurczewski L; Yajnik V
J Thromb Thrombolysis; 2019 Jul; 48(1):167-170. PubMed ID: 30968302
[TBL] [Abstract][Full Text] [Related]
28. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
29. Rash associated with piperacillin/tazobactam administration in infectious mononucleosis.
LeClaire AC; Martin CA; Hoven AD
Ann Pharmacother; 2004 Jun; 38(6):996-8. PubMed ID: 15113982
[TBL] [Abstract][Full Text] [Related]
30. Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit.
Boyce K; Brar H; Stabler SN
J Clin Pharm Ther; 2016 Dec; 41(6):730-732. PubMed ID: 27670947
[TBL] [Abstract][Full Text] [Related]
31. Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis.
Kyriakou A; Zagalioti SC; Patsatsi A; Galanis N; Lazaridou E
Case Rep Dermatol Med; 2019; 2019():3273987. PubMed ID: 31179136
[TBL] [Abstract][Full Text] [Related]
32. Contrast Media-Induced Immune Hemolytic Anemia.
Al Ghailani HH; Al Alawi AM; Al Hashim AH
Cureus; 2021 Apr; 13(4):e14522. PubMed ID: 34012735
[TBL] [Abstract][Full Text] [Related]
33. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.
Sweet RL; Roy S; Faro S; O'Brien WF; Sanfilippo JS; Seidlin M
Obstet Gynecol; 1994 Feb; 83(2):280-6. PubMed ID: 8290195
[TBL] [Abstract][Full Text] [Related]
34. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
[TBL] [Abstract][Full Text] [Related]
35. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
Kuti JL; Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP
Diagn Microbiol Infect Dis; 2015 Sep; 83(1):53-5. PubMed ID: 26003469
[TBL] [Abstract][Full Text] [Related]
36. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
[TBL] [Abstract][Full Text] [Related]
37. Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections.
Fry W; McCafferty S; Gooday C; Nunney I; Dhatariya KK
Diabetes Ther; 2018 Feb; 9(1):219-228. PubMed ID: 29302933
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced immune hemolytic anemia.
Garratty G
Hematology Am Soc Hematol Educ Program; 2009; ():73-9. PubMed ID: 20008184
[TBL] [Abstract][Full Text] [Related]
39. [Drug-induced immune hemolytic anemia: a retrospective study of 10 cases].
Bollotte A; Vial T; Bricca P; Bernard C; Broussolle C; Sève P
Rev Med Interne; 2014 Dec; 35(12):779-89. PubMed ID: 24908632
[TBL] [Abstract][Full Text] [Related]
40. Drug-Induced Immune Hemolytic Anemia due to Amoxicillin-Clavulanate: A Case Report and Review.
Chan Gomez J; Saleem T; Snyder S; Joseph M; Kanderi T
Cureus; 2020 Jun; 12(6):e8666. PubMed ID: 32699666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
